IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant:

Chensheng LI et al.

Title:

TRANSDERMAL ADMINISTRATION OF ACE INHIBITORS

Appl. No.:

10/014,785

Filing Date: 12/14/2001

Examiner:

I. Ghali

Art Unit:

1615

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR §1.56**

Mail Stop PATENT APPLICATION Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of a document known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a prima facie art reference against the claims of the present application.

04/22/2004 MGEBREM1 00000066 10014785

01 FC:1806

180.00 OP

TIMING OF THE DISCLOSURE

The listed document is being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

The document is in English.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

A fee in connection with submission of an information disclosure statement under 37 CFR §1.97(c) in the amount of \$180.00 in accordance with 37 CFR §1.17(p) is attached.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Date 21 April 2004

FOLEY & LARDNER LLP Washington Harbour 3000 K Street, N.W., Suite 500 Washington, D.C. 20007-5143 Telephone: (202) 672-5585 Facsimile: (202) 672-5399 Respectfully submitted,

James M. Silbermann Attorney for Applicant Registration No. 40,413

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.						
	Substitute for for	rm 1449B	/PTO		Complete if Known	
	INFORMATION	DISCLO	SURE	Application Number	10/014,785	010
	STATEMENT B	Y APPL	ICANT	Filing Date	12/14/2001	Re/
	D-4- 0-4	:	100 0 4 0001	First Named Inventor	Chensheng LI	4.
	Date Sur	omittea:	APR 2 1 2004	Group Art Unit	1615	APR 2
	(use as many shee	ets as ne	ecessary)	Examiner Name	I. Ghali	27 2004 60
Sheet	1	of	1	Attorney Docket Number	041457-0635	The state of the s

U.S. PATENT DOCUMENTS								
Examiner Initials*		U.S. Patent Document		N	Date of Publication of	Pages, Columns, Lines, Where Relevant		
	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)			ode ⁵	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
									-

NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	A1	Li et al., "THE STUDY OF TRANSDERMAL ADMINISTRATION OF ACE INHIBITORS AND IMPROVED ABSORPTION OF THEIR PRODRUGS", Noven Pharmaceuticals, Inc., November 2, 2000 (2 pgs.)						
A Part of the second of the se								

Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.